Kanaph Therapeutics is a drug discovery and pre-clinical stage biotech based in Korea, with a large and small molecule two-track strategy for the development of first-in-class and best-in-class therapeutics in immuno-oncology, targeted therapy and autoimmune (ophthalmology) diseases.
Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
Company Details
- Employees
- 16
- Address
- 5f, 3, Itaewon-Ro 55ga-Gil, Yongsan-Gu,, Seoul,04348,korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.kanaphtx.com
- HQ
- Seoul
Kanaph Therapeutics Questions
Kanaph Therapeutics's website is http://www.kanaphtx.com
Kanaph Therapeutics's LinkedIn profile is https://kr.linkedin.com/company/kanaph
Kanaph Therapeutics has
16 employees.
View email and phone details for 16
employees at Kanaph Therapeutics.
Kanaph Therapeutics's industry is
Pharmaceutical Manufacturing
Kanaph Therapeutics's top competitors are
Adarx Pharmaceuticals Inc.,
Insmed Incorporated,
Axcelead, Inc.,
Onconic Therapeutics,
Samsung Medical Center,
Ionis Pharmaceuticals, Inc.,
Voronoi Inc.,
Vivid Biosciences,
Lotte Biologics,
Altrubio Inc..
Kanaph Therapeutics's categories are Pharmaceutical Manufacturing
